Day One Biopharmaceuticals is developing therapies for patients of all ages with life-threatening diseases. The most common childhood brain cancer is pediatric low-grade glioma (pLGG), and it currently lacks effective cures. Through partnering with leading clinical oncologists, families and scientists, Day One is identifying, acquiring and developing cancer treatments. Day One’s lead product, DAY101 (tovorafenib), is in Phase 1/2 clinical trials for treatment against pLGG. DAY101 is an orally-taken, brain-penetrant pan-RAF inhibitor. Day One’s pipeline also includes pimasertib, a small molecule inhibitor of MEK-1/-2.

<p>Day One Biopharmaceuticals is developing therapies for patients of all ages with life-threatening diseases. The most common childhood brain cancer is pediatric low-grade glioma (pLGG), and it currently lacks effective cures. Through partnering with leading clinical oncologists, families and scientists, Day One is identifying, acquiring and developing cancer treatments. Day One’s lead product, DAY101 (tovorafenib), is in Phase 1/2 clinical trials for treatment against pLGG. DAY101 is an orally-taken, brain-penetrant pan-RAF inhibitor. Day One’s pipeline also includes pimasertib, a small molecule inhibitor of MEK-1/-2.</p>


Day One Biopharmaceuticals


                                            Our advocacy team                                        

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 - StockTitan

www.everydaysupport.com

Day one Biopharmaceuticals head of R&D sells $399,339 in stock - Investing.com

Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug - Endpoints News

Expanded access

Day One’s Ojemda Gets FDA Accelerated Approval for Pediatric Brain Tumor - BioSpace

 Raf kinase inhibitors for treating tumors harboring gene fusions 

Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors - GlobeNewswire

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Consensus Target Price from Analysts - MarketBeat

 Day One Announces Sale of Priority Review Voucher for $108 Million 

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor - Yahoo Finance

Publications & posters


                                            FIREFLY-1 Clinical Trial                                        

 Day One Biopharmaceuticals Executives Sell Shares Worth Over $2.4 Million 


                                    
                                        
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                        
                                        
                                            
                                                
                                            
                                        
                                    
                                

Day One takes on Novartis with FDA nod for Ojemda in broader common childhood brain tumor use - FiercePharma

“The Day One Talk”

Day One Biopharmaceuticals Announces Leadership Transition - TipRanks

Day One Biopharmaceuticals: Sales Figures In The Crosshairs... And What Else? - Seeking Alpha

Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk - Nasdaq

With $111M upfront investment, Ipsen secures ex-US rights to Day One's pediatric cancer med - FiercePharma

Visit everydaysupport.com

Partnering

Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy - Pharmaceutical Technology

Day One Biopharmaceuticals: Still Uncertainty After FDA Approval (NASDAQ:DAWN) - Seeking Alpha

 Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated 

Insider Sale at Day One Biopharmaceuticals Inc (DAWN) - Yahoo Finance

Day One Biopharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference - StockTitan

 What 7 Analyst Ratings Have To Say About Day One Biopharmaceutical 

ojemdahcp.com


                    Learn more about our mission                


                                            RESOURCES                                        

 7 Analysts Have This to Say About Day One Biopharmaceutical 

Childhood cancer-focused Day One snags Gilead alum ...

 Day One Biopharmaceuticals 10% owner increases holding with ~$15M stock purchase 

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development - GlobeNewswire

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey

Day One spends day 2 hitting up public markets for $150M ...

Geode Capital Management LLC Boosts Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat

Childhood cancer-focused Day One tees up $100M IPO

 Should You Buy Day One Biopharmaceuticals Inc (DAWN) Stock After it Has Gained 10.25% in a Week? 

Charles Schwab Investment Management Inc. Acquires 64,700 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat

Childhood-cancer-focused Day One banks $130M for pan ...

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Significant Decrease in Short Interest - MarketBeat

 Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair (NASDAQ:DAWN) 

 Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M 

 Vice President, Product Team Leader job with Day One Biopharmaceuticals | 2888322 

 Combination of raf inhibitor and mek inhibitor 

CBTN Partners with Day One to Drive New Therapies for Pediatric Brain Tumors - PR Newswire

Join us at the Patient Recruitment for Rare Disease Trials Summit, December 10-12 in Boston! Our very own Kelli Wright, Director of Patient Advocacy, will be sharing examples on how to include patient input into clinical trial design at any stage of your program.

Learn more about the conference here: https://ter.li/7b1o12

Ipsen and Day One in ex-US tovorafenib deal for most common childhood brain tumor - The Pharma Letter

 Day One Biopharmaceuticals inks research collaboration with Swedish biotech 

Read their stories

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - GlobeNewswire

 FDA Drug Approval Marks a New Day for Treating Pediatric Brain Cancer 

Day One Biopharmaceuticals Reports Strong Q3 Growth - TipRanks

FDA Drug Approval Marks a New Day for Treating Pediatric Brain Cancer - MedCity News

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance

We’re looking forward to attending the Piper Sandler Annual Healthcare Conference. Day One management will participate in a fireside chat on Tuesday, December 3 at 3:00 PM ET. A live webcast of the discussion will be available here: https://bit.ly/3UMCys7
 
Learn more: https://bit.ly/3URzxqv


                                            DAY301                                        

 With $111M upfront investment, Ipsen secures ex-US rights to Day One's pediatric cancer med 

Read Nora’s Story

 Day One Biopharmaceuticals management to meet with Piper Sandler 

Ipsen builds again, licensing Day One glioma drug - pharmaphorum

 Day One Biopharmaceuticals files automatic mixed securities shelf 

 Day One Biopharma in-licenses VRK1 from Sprint Bioscience 

Day One debuts with $60M to change cancer care ...

The Day One team is excited to be at the 29th Annual Meeting of the Society for Neuro-Oncology in Houston this week! Stop by our booth (423) to hear how we're redefining what's possible for people of all ages living with cancer.

Investigators from the phase 2 FIREFLY-1 trial will be presenting data on Friday, November 22. See poster presentation details below. Learn more: https://bit.ly/4eqA1vg

Day One jets off with Sprint's VRK1 program for up to $316M


                                            Learn about OJEMDA™                                        

Compliance

Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance

 Day One’s Ojemda Gets FDA Accelerated Approval for Pediatric Brain Tumor 

 Pediatric Brain Tumor Foundation celebrates FDA approval of Day One Biopharmaceuticals' OJEMDA™, new ... 

Day One Expands Pipeline with Potential First-in-Class - GlobeNewswire

See our pipeline

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - StockTitan

 Day One inks $1.2B biobucks pact for MabCare’s solid tumor ADC 


              CBTN Partners with Day One to Drive New Therapies for Pediatric Brain Tumors
            

Day One enters ADC field, going after a target that once attracted AbbVie and now Genmab - Endpoints News

Investigator-sponsored research

 Day One pressures Novartis with FDA nod for novel RAF inhibitor 

Day One Announces Oversubscribed $175.0 Million Private Placement - GlobeNewswire

Solving for the medical and business case in pediatric cancer — Day One - BioCentury

High Growth Tech Stocks to Watch in December 2024 - Simply Wall St

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor - GlobeNewswire

 Oral liquid suspension of pan-raf kinase inhibitor 

 Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval 

 Day One Reports First Quarter 2024 Financial Results and Corporate Progress 

Day One Biopharmaceuticals CEO sells $139,420 in stock - Investing.com

Ipsen and Day One enter into exclusive ex-U.S. licensing - GlobeNewswire

Report allegations

 Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects 

Leadership

Nature Medicine

 Where Day One Biopharmaceutical Stands With Analysts 

We are excited to share our recently published manuscript in 𝘕𝘦𝘶𝘳𝘰-𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺, which details radiographic and visual response to tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial. These findings from a post-hoc analysis contribute to our understanding of treatment outcomes in this challenging condition.

Read More: https://lnkd.in/g7tw3s-Q

Day One Biopharmaceuticals

Business:

Drug notes:

About: